| Name | Title | Contact Details |
|---|
A paradigm shift in prosthetic comfort and quality of life. The Socket-less Socket™ fits like a sneaker providing comfort and control for all amputation levels.
Purdue Pharma is a research-based pharmaceutical company with its headquarters and manufacturing operations located in Pickering, Ontario. The company is a leader in the research and development of medicines for the treatment of pain and ADHD. Privately held, Purdue Pharma Canada is independently associated with the worldwide Purdue/Napp/Mundipharma group of companies.
Zogenix is a global pharmaceutical company committed to developing and commercializing therapies with the potential to transform the lives of patients and their families living with rare diseases. The company has two late-stage development programs underway: FINTEPLA® (ZX008, fenfluramine oral solution) for the treatment of seizures associated with Dravet and Lennox-Gastaut syndromes, two rare and often-catastrophic childhood-onset epilepsies, and MT1621, a novel substrate enhancement therapy for the treatment of a rare genetic disorder called TK2 deficiency.
Slayback Pharma LLC is a specialty pharmaceutical company focused on developing, manufacturing and sourcing of complex generic pharmaceutical products, with a specific emphasis on complex injectables and other non-solid oral products. Slayback has created a unique portfolio of complex generics by smart product selection and execution and connecting various dots through a network of contract R&D laboratories and manufacturing organizations, comprising smart and rapid development capabilities, sophisticated manufacturing and innovative drug delivery technologies.
Intra-Cellular Therapies is a biopharmaceutical company developing novel drugs, leveraging technology from the lab of Nobel laureate Dr. Paul Greengard, for the treatment of neuropsychiatric and neurodegenerative diseases. The Company is developing its lead drug candidate, lumateperone, a first-in-class molecule, which is in Phase 3 clinical development for the treatment of schizophrenia, bipolar depression, and agitation associated with dementia, including Alzheimer`s disease. The Company is also utilizing its phosphodiesterase (PDE) platform and other proprietary chemistry platforms to develop drugs for the treatment of CNS and other disorders. The lead compound in the PDE platform, ITI-214, a PDE1 inhibitor is being developed for the treatment of CNS and non-CNS indications.